Talvey Gets Accelerated Approval for Myeloma Treatment
The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.
Source: curetoday.com
Page 5 - Multiple Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multiple Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multiple Myeloma Program Today - Breaking & Trending Today
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...
Source: prnewswire.com
FDA Grants Accelerated Approval to Talquetamab-tgvs for Patients With Heavily Pretreated Multiple Myeloma
Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.
Source: pharmacytimes.com
New Blood Cancer Therapy Gives a New Lease on Life To 73% of Patients
New Blood Cancer Therapy Gives a New Lease on Life To 73% of Patients - Industry Tap
Source: industrytap.com
New drugs, if approved, could have big impact in 2023
Predicting when new drugs come to market in the United States has never been an exact science, but several drugs that could be approved in 2023 could have a significant impact on health for millions of people.
Source: upi.com